Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Wednesday 09 May, 2007

XTL Biopharm Ltd

XTL to Present at the Acumen BioFin Conference


            XTL Biopharmaceuticals to Present at the Acumen BioFin             
           Rodman & Renshaw 4th Annual Global Health Care Conference           

VALLEY COTTAGE, NEW YORK, May 9, 2007 - XTL Biopharmaceuticals Ltd. (NASDAQ:
XTLB; LSE: XTL; TASE: XTL) announced today that Ram Waisbourd, the Company's
Vice President of Business Development, is scheduled to present at the Acumen
BioFin Rodman & Renshaw 4th Annual Global Health Care Conference 
(www.rodmanandrenshaw.com/eu07conference). Mr. Waisbourd will present an
overview of the Company including an overview of Bicifadine, the Company's
recently in-licensed late-stage clinical compound for the treatment of
neuropathic pain. Mr. Waisbourd's presentation will take place on Tuesday, May
15, 2007, at 8:40am local time in Monte Carlo (2:40am Eastern Daylight Time and
9:40am Israel Daylight Time), at the Le Meridien Beach Plaza Hotel in Monte
Carlo, Monaco.

A live audio webcast of Mr. Waisbourd's presentation will be available at: 
http://www.wsw.com/webcast/rrshq11/xtlb. An archived version of the webcast will
be available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of neuropathic pain and
hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of neuropathic pain. In addition, XTL is
developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the
hepatitis C virus polymerase. XTL-2125 is currently in a Phase I clinical trial
in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a
combination of two monoclonal antibodies against the hepatitis C virus. XTL's
hepatitis C pipeline also includes several families of pre-clinical hepatitis C
small molecule inhibitors.  XTL also has an active in-licensing and acquisition
program designed to identify and acquire additional drug candidates. XTL is
publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ:
XTLB; LSE: XTL; TASE: XTL).

Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225

                                                                               
                                

                                                                               

                                                                                                                  

a d v e r t i s e m e n t